A class action lawsuit was filed against Telix Pharmaceuticals (ASX:TLX) on behalf of investors in Telix, who acquired securities in the firm between Feb. 21 and Aug. 28, alleging that Telix materially overstated the progress being made about its prostate cancer therapy candidates and the quality of its supply chain and manufacturing partners, according to a Friday Australian bourse filing.

Shareholders' rights firm Hagens Berman said that the lawsuit alleges that Telix made false and misleading statements while failing to disclose crucial information to investors, focused on the "propriety" of Telix's statements relating to its TLX591 and TLX592 prostate cancer therapy candidates, as well as its Zircaix kidney cancer detection candidate.

The investors were "surprised" by a US Securities and Exchange Commission investigation into the company's disclosures regarding the development of the prostate cancer therapy candidates, which sent the price of Telix's American depositary shares sharply lower, per the complaint.

Telix did not immediately respond to MT Newswires' request for comment.

Its shares fell 3% in recent trading on Friday.